Your search for oral corticosteroids returned 123 results

The authors reported that ACQ scores (P=0.04) and oral corticosteroid use (P=0.04) were significantly reduced in high severity completers (n=21) receiving escitalopram.

Male patients exhibited the highest rates of oral steroid prescriptions.

The first-in-class tyrosine kinase inhibitor masitinib decreased asthma exacerbations greater than placebo in patients with severe asthma uncontrolled by oral corticosteroids.

GlaxoSmithKline announced that the primary endpoint for its Phase 3 study of mepolizumab was met for the reduction in the frequency of exacerbations, in patients with severe eosinophilic asthma.

Consistent reductions in asthma attacks and improvements in lung function across a broad population of uncontrolled asthma patients.

Results found that infants with an unknown epilepsy etiology, a normal MRI, an EEG displaying hypsarrhythmia, or those already receiving an AED were more likely to be administered ACTH.

The disease can be life threatening. Phase 3 study results released last March demonstrated Rituxan substantialy improved pemphigus vulgaris remission rates and successful tapering.

“Immunomodulatory therapy should be considered early, because NSAIDs or a short course of oral corticosteroids may be sufficient for symptom remission in recent-onset cases, whereas those with long-standing symptoms often require more intensive and prolonged immunotherapeutic interventions,” the authors write.

The FDA has approved Simponi (golimumab for subcutaneous injection; Janssen Biotech) to induce and maintain clinical response in adults with ulcerative colitis.

The designation was based on data from the Phase 2b PATHWAY trial that evaluated 3 doses of tezepelumab as add-on therapy in patients with a history of asthma exacerbations and uncontrolled asthma receiving inhaled corticosteroids/long-acting β-agonist with or without oral corticosteroids and additional asthma controllers vs placebo.